Loading
Latest filing published 08 Jun 2022 for Cortexyme, Inc., €29k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
All filings by Leslie Holsinger on record concern IRulya Therapeutics Inc., in the capacity of chief executive. Between 3 March 2022 and 6 June 2022, the trades on record add up to 2 filings.
Not one of the filings records a straightforward purchase or sale on the market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
On 8 June 2022 came the latest disclosure, a share grant for €29k in IRulya Therapeutics Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations